Literature DB >> 6416698

Cooperative studies of chemoprophylaxis after transurethral resection of bladder tumors.

M Pavone-Macaluso, M Tripi, G B Ingargiola.   

Abstract

Large cooperative trials are more likely than series studied by small groups to bring about significant progress in the field of intravesical adjuvant chemotherapy of superficial bladder tumor. Multicenter randomized trials involving large numbers of patients have been conducted in Europe by the EORTC Urological Group. The Group's main objectives were to compare the efficacy of thio-TEPA, VM-26, epodyl, Adriamycin, and cisplatin, against no treatment, and to study the prophylactic effect of oral pyridoxine and evaluate the main prognostic factors. The results obtained so far are reported. Preliminary information is also given about the Blinst study, a multicenter open investigation of local chemotherapy with doxorubicin (Adriamycin), with special reference to evaluation of the importance of different modalities of treatment with a single drug.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6416698     DOI: 10.1007/BF00256711

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  8 in total

1.  Topical instillation of doxorubicin hydrochloride in the treatment of recurring superficial transitional cell carcinoma of the bladder.

Authors:  M D Banks; J E Pontes; R M Izbicki; J M Pierce
Journal:  J Urol       Date:  1977-11       Impact factor: 7.450

2.  Thiotepa bladder instillations: therapy and prophylaxis for superficial bladder tumors.

Authors:  R J Veenema; A L Dean; A C Uson; M Roberts; F Longo
Journal:  J Urol       Date:  1969-05       Impact factor: 7.450

3.  Preliminary evaluation of VM-26: a new epipodophyllotoxin derivative, in the treatment of urogenital tumours.

Authors:  M Pavone-Macaluso; G Caramia; F P Rizzo; V Messana
Journal:  Eur Urol       Date:  1975       Impact factor: 20.096

Review 4.  Local chemotherapy in bladder cancer treatment.

Authors:  M Pavone-Macaluso; G B Ingargiola
Journal:  Oncology       Date:  1980       Impact factor: 2.935

5.  The European Organization for Research on Treatment of Cancer. Genito-urinary Tract Cancer Cooperative Group.

Authors:  M De Pauw; C Bouffioux; J Casselman; C Shulman; B Vergison; L Denis
Journal:  Acta Urol Belg       Date:  1980-04

6.  The effect of intravesical thio-tepa on normal and tumor urothelium.

Authors:  P T Nieh; J J Daly; J A Heaney; N M Heney; G R Prout
Journal:  J Urol       Date:  1978-01       Impact factor: 7.450

7.  Comparisons of placebo, pyridoxine, and topical thiotepa in preventing recurrence of stage I bladder cancer.

Authors:  D Byar; C Blackard
Journal:  Urology       Date:  1977-12       Impact factor: 2.649

8.  Prophylactic chemotherapy of superficial transitional cell bladder carcinoma: an EORTC randomized trial comparing thiotepa, an epipodophyllotoxin (VM26) and TUR alone.

Authors:  C C Schulman; M Robinson; L Denis; P Smith; G Viggiano; M de Pauw; O Dalesio; R Sylvester
Journal:  Eur Urol       Date:  1982       Impact factor: 20.096

  8 in total
  2 in total

1.  Prophylaxis of superficial bladder cancer with instillation of adriamycin or mitomycin C.

Authors:  S Isaka; T Okano; J Shimazaki; T Igarashi; S Murakami; T Higa; T Ishikawa; S Zama; S Kataumi; Z Kataumi
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

2.  Organ distribution of Adriamycin after intravesical instillation with or without Tween 80 in the rat.

Authors:  S Hellsten; B Axelsson; S Eksborg; C Lindkvist
Journal:  Urol Res       Date:  1988
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.